- Trials with a EudraCT protocol (55)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
55 result(s) found for: Penile Carcinoma.
Displaying page 1 of 3.
| EudraCT Number: 2019-003022-24 | Sponsor Protocol Number: N19IFC | Start Date*: 2019-10-15 | |||||||||||||||||||||
| Sponsor Name:NKI-AVL | |||||||||||||||||||||||
| Full Title: INFLUENCE (INtra-operative evaluation of a novel FLUorescENt C-mEt tracer in penile and tongue cancer) | |||||||||||||||||||||||
| Medical condition: Penile cancer and tongue cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2018-000603-17 | Sponsor Protocol Number: N18PER | Start Date*: 2018-09-05 | |||||||||||
| Sponsor Name:Antoni van leeuwenhoek | |||||||||||||
| Full Title: PERICLES (PEnile cancer Radio- and Immunotherapy CLinical Exploration Study) – a Phase 2 study of atezolizumab with or without radiotherapy in penile cancer | |||||||||||||
| Medical condition: | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001963-19 | Sponsor Protocol Number: CaboPen | Start Date*: 2019-05-16 | |||||||||||
| Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
| Full Title: Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen) | |||||||||||||
| Medical condition: Patients with advanced penile squamous cell carcinoma (PSCC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-000707-28 | Sponsor Protocol Number: ICR-CTSU/2008/10016 | Start Date*: 2009-03-23 | |||||||||||
| Sponsor Name:The Institute of Cancer Research [...] | |||||||||||||
| Full Title: A Phase II Trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic carcinoma of the penis | |||||||||||||
| Medical condition: Locally advanced and metastatic carcinoma of the penis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-001172-11 | Sponsor Protocol Number: MedOPP239 | Start Date*: 2020-03-10 | |||||||||||
| Sponsor Name:Medica Scientia Innovation Research (MedSIR) | |||||||||||||
| Full Title: A Multicenter, Open-Label, Single-ARm, PHase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile SquamoUS Cell Carcinoma. ORPHEUS Phase II Study of the Efficacy ... | |||||||||||||
| Medical condition: Unresectable locally advanced or metastatic penile squamous cell carcinoma (PSqCC). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: ES (Ongoing) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-003127-22 | Sponsor Protocol Number: SOG-CPE-2014-03 | Start Date*: 2015-01-13 | |||||||||||
| Sponsor Name:SOGUG (Spanish Oncology Genitourinary Group) | |||||||||||||
| Full Title: Phase II study with pazopanib and weekly paclitaxel in metastatic or locally advanced squamous penile carcinoma patients previously treated with cisplatin based chemotherapy | |||||||||||||
| Medical condition: Metastatic or locally advanced squamous penile carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-002592-34 | Sponsor Protocol Number: ICR-CTSU/2012/10036 | Start Date*: 2013-07-12 | |||||||||||
| Sponsor Name:The Institute of Cancer Research | |||||||||||||
| Full Title: A Phase II Trial of Vinflunine chemotherapy in locally advanced and metastatic carcinoma of the penis | |||||||||||||
| Medical condition: Locally advanced and metastatic carcinoma of the penis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002061-30 | Sponsor Protocol Number: 4.0 | Start Date*: 2016-07-18 | ||||||||||||||||||||||||||
| Sponsor Name:University Hospital Southampton NHS Foundation Trust | ||||||||||||||||||||||||||||
| Full Title: Therapeutic HPV vaccine trial +/- anti-CD40 in HPV-driven squamous cell carcinoma. | ||||||||||||||||||||||||||||
| Medical condition: HPV induced cancers such as Head and Neck Squamous Cell Carcinoma (HNSCC), Anogenital Cancer, Cervical Cancer, Penile Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2021-004277-31 | Sponsor Protocol Number: E012-HPV | Start Date*: 2021-12-23 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:eTheRNA immunotherapies NV | ||||||||||||||||||||||||||||||||||||||
| Full Title: A phase I/IIa open label study to assess the safety, tolerability, immunogenicity and clinical activity of EI-201 mRNA immunotherapy given intravenously in subjects with recurrent or metastatic HPV... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Incurable recurrent or metastatic (R/M) HPV16-positive (HPV16+) tumors (e.g. oropharyngeal cancer, cervical, vulvar, vaginal, anal, penile cancer, etc.) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) DE (Completed) NL (Completed) PL (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-000907-34 | Sponsor Protocol Number: H-200-001 | Start Date*: 2021-11-11 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Hookipa Biotech GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Ongoing) NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-004678-41 | Sponsor Protocol Number: UC_0160/1406 | Start Date*: 2016-01-21 | |||||||||||
| Sponsor Name:UNICANCER | |||||||||||||
| Full Title: Etude prospective de phase II d’évaluation d’une prise en charge multimodale des métastases ganglionnaires inguinales des carcinomes épidermoïdes du pénis par lymphadénectomie bilatérale et chimiot... | |||||||||||||
| Medical condition: Tumeur du pénis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2013-001985-41 | Sponsor Protocol Number: 09-09 | Start Date*: 2013-08-27 | |||||||||||
| Sponsor Name:Onconova Therapeutics Inc. | |||||||||||||
| Full Title: A Phase II Study of Oral Rigosertib in Patients with Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma | |||||||||||||
| Medical condition: Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-002336-14 | Sponsor Protocol Number: | Start Date*: 2014-09-05 | |||||||||||
| Sponsor Name:University Hosptial Bristol NHS Foundation trust | |||||||||||||
| Full Title: A phase II study of Cabazitaxel chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis. | |||||||||||||
| Medical condition: Relapsed, locally advanced and/or metastatic carcinoma of the penis. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-002006-51 | Sponsor Protocol Number: MK-3475-975 | Start Date*: 2019-12-11 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
| Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (K... | |||||||||||||
| Medical condition: Esophageal Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) EE (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) RO (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002799-28 | Sponsor Protocol Number: TG4001.12 | Start Date*: 2020-03-19 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Transgene | ||||||||||||||||||||||||||||||||||||||
| Full Title: A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of the he... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: HPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of head and neck, cervical cancer, vulvar cancer, vaginal cancer, penile cancer, anal cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2020-001907-18 | Sponsor Protocol Number: MK-6482 | Start Date*: 2020-09-14 | ||||||||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
| Full Title: Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | ||||||||||||||||||
| Medical condition: Advanced Renal Cell Carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-004034-38 | Sponsor Protocol Number: MK-7684A-002 | Start Date*: 2021-04-19 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||
| Full Title: A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-... | |||||||||||||
| Medical condition: Non Small Cell Lung cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-005405-26 | Sponsor Protocol Number: MK-3475-06A | Start Date*: 2022-07-25 | |||||||||||
| Sponsor Name:MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC. | |||||||||||||
| Full Title: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER... | |||||||||||||
| Medical condition: Esophageal Squamous Cell Carcinoma (ESCC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) NO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-005443-76 | Sponsor Protocol Number: MK-3475-06B | Start Date*: 2022-07-14 | |||||||||||
| Sponsor Name:MERCK SHARP & DOHME LLC. UNA SUSSIDIARIA DI MERCK & CO. INC. | |||||||||||||
| Full Title: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatm... | |||||||||||||
| Medical condition: Esophageal Squamous Cell Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002682-34 | Sponsor Protocol Number: 2019/0398/HP | Start Date*: 2023-04-20 | |||||||||||||||||||||
| Sponsor Name:CHU de Rouen | |||||||||||||||||||||||
| Full Title: Interest of early erectile rehabilitation with Sildenafil after radiotherapy and proctectomy for rectal cancer: Randomized controlled trial - RECTIL | |||||||||||||||||||||||
| Medical condition: Men treated with proctectomy and neoadjuvant radiation therapy for rectal cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.